Search
Specialized Working Groups
EHA partners with Specialized Working Groups (SWGs) to foster science and to spread knowledge in basic, translational and clinical research in hematology in Europe.
Read moreASCAT 2023
EHA joins forces with the British Society of Haematology (BSH) & Annual Academy of Sickle Cell and Thalassaemia Conference (ASCAT) in organizing the 18th Annual Sickle Cell & Thalassaemia Conference.
Read moreEHA Research Conference 2025
Dates: March 17-20, 2025
Location: Málaga, Spain
Chairs: Alba Maiques Diaz, Ruud Delwel, Panagiotis Ntziachristos, Marcus Buschbeck, Mark Dawson,
Özgen Deniz, Kimberly Stegmaier, and Nina Cabezas Wallscheid
Registration is now open
EHA is proud to announce the third edition of the EHA Research Conference, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis".…
Highlights of Past EHA (HOPE) Latin America (LA) 2022 - report
November 17-19, 2022 – Barranquilla, Colombia
Meeting chairs:
D McLornan, Vice-Chair Global Outreach Program Committee, European Hematology Association (EHA)
V Abello Polo, President, Asociación Colombiana de Hematología y Oncología (ACHO)
This year, the HOPE LA meeting was held in collaboration with the Asociación Colombiana…
EHA-SWG Scientific Meeting on Acquired Aplastic Anemia
EHA & the EHA Scientific Working Group on Granulocyte and Constitutional Marrow Failure Syndromes are happy to announce their recent collaboration in organizing a virtual meeting program on Acquired Aplastic Anemia.
Read moreSWG Committee
Current committee members
Konstanze Döhner, Germany (Chair (EHA Board member))
Dominique Bonnet, United Kingdom (Vice-Chair)
Immacolata Andolfo, Italy
Igor Aurer, Croatia
Raul Cordoba, Spain
Hermann Einsele, Germany
Eleni Gavriilaki, Greece (Representative, Young EHA Committee)
Kirsten Gronbaek, Denmark (EHA Board)
Esther Oliva, Italy
Marc Raaijmakers, The Netherlands
Josef Vormoor, The Netherlands
Aim
The SWG…
Pomalidomide prolongs survival in refractory myeloma patients
MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…
Read moreEnjoy Amsterdam like a Local
EHA24 is just around the corner, and we could not be more excited about the Congress program (especially the YoungEHA track – great science, interesting discussions, and food for thought are waiting for you)! As attending the Congress is also…
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- »